A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specifi...
- Lymphoma, T-Cell
- Immunoblastic Lymphadenopathy
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, T-Cell, Peripheral
Age: 18 years - 66+
Gender: All